AR006514A1 - A MACROLID, ITS USES, A PROCESS TO PRODUCE IT, A BIOLOGICALLY PURE ISOLATE CAPABLE OF PRODUCING IT, AND A PHARMACEUTICAL COMPOSITION THAT IT INCLUDES - Google Patents

A MACROLID, ITS USES, A PROCESS TO PRODUCE IT, A BIOLOGICALLY PURE ISOLATE CAPABLE OF PRODUCING IT, AND A PHARMACEUTICAL COMPOSITION THAT IT INCLUDES

Info

Publication number
AR006514A1
AR006514A1 ARP960103427A AR10342796A AR006514A1 AR 006514 A1 AR006514 A1 AR 006514A1 AR P960103427 A ARP960103427 A AR P960103427A AR 10342796 A AR10342796 A AR 10342796A AR 006514 A1 AR006514 A1 AR 006514A1
Authority
AR
Argentina
Prior art keywords
macrolide
producing
pharmaceutical composition
produce
inclusive
Prior art date
Application number
ARP960103427A
Other languages
Spanish (es)
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9513596.8A external-priority patent/GB9513596D0/en
Priority claimed from GBGB9515495.1A external-priority patent/GB9515495D0/en
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of AR006514A1 publication Critical patent/AR006514A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se refiere a un macrólido el cual tiene: i) las posiciones 2 a 6 inclusive, del anillo macrocíclico que se proporcionan por un residuo de ácidopiperidazinilcarboxílico; y/o ii)las posiciones 7 a 9 inclusive, del anillo macrocíclicoque se proporcionan por un residuo alfa-aminoácido aromático;y/o iii) las posiciones 10 a 12 inclusive, del anillo macrocíclico que se proporcionan por un residuo alfa-aminoácido alifático, en forma libreo protegida, o una sal del mismo.Además, s e refiere al uso de dicho macrólido para la preparación de un medicamento para uso como inmunosupresor, al uso dedicho macrólido como un reactivo en un inmunoensayo de desplazamiento para una ciclosporina u otros compuestos que unenciclofilina , a un proceso paraproducir dicho macrólido, a un aislado biológicamente puro de la cepa Streptomyces sp A92-308110 (DSM 9954) o un mutante, recombinante o formamodificada del mismo, el cual es capaz de producir dichomacrólido, y a una composición farmacéutica que comprende a dicho macrólido en asociación con undiluyente o portador farmacéuticamente aceptable.It refers to a macrolide which has: i) positions 2 to 6 inclusive, of the macrocyclic ring that are provided by a piperidazinylcarboxylic acid residue; and / or ii) positions 7 to 9 inclusive, of the macrocyclic ring that are provided by an aromatic alpha-amino acid residue; and / or iii) positions 10 to 12 inclusive, of the macrocyclic ring that are provided by an aliphatic alpha-amino acid residue In addition, it refers to the use of said macrolide for the preparation of a drug for use as an immunosuppressant, to the use of said macrolide as a reagent in a displacement immunoassay for a cyclosporin or other compounds. than unencyclophilin, to a process to produce said macrolide, to a biologically pure isolate of the Streptomyces sp A92-308110 (DSM 9954) strain or a mutant, recombinant or modified form thereof, which is capable of producing dichomacrolide, and to a pharmaceutical composition that It comprises said macrolide in association with a pharmaceutically acceptable diluent or carrier.

ARP960103427A 1995-07-04 1996-07-03 A MACROLID, ITS USES, A PROCESS TO PRODUCE IT, A BIOLOGICALLY PURE ISOLATE CAPABLE OF PRODUCING IT, AND A PHARMACEUTICAL COMPOSITION THAT IT INCLUDES AR006514A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9513596.8A GB9513596D0 (en) 1995-07-04 1995-07-04 Organic compounds
GBGB9515495.1A GB9515495D0 (en) 1995-07-28 1995-07-28 Organic compounds

Publications (1)

Publication Number Publication Date
AR006514A1 true AR006514A1 (en) 1999-09-08

Family

ID=26307320

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960103427A AR006514A1 (en) 1995-07-04 1996-07-03 A MACROLID, ITS USES, A PROCESS TO PRODUCE IT, A BIOLOGICALLY PURE ISOLATE CAPABLE OF PRODUCING IT, AND A PHARMACEUTICAL COMPOSITION THAT IT INCLUDES

Country Status (17)

Country Link
EP (1) EP0836616A1 (en)
JP (1) JPH11509092A (en)
KR (1) KR19990028724A (en)
CN (1) CN1193979A (en)
AR (1) AR006514A1 (en)
AU (1) AU708004B2 (en)
BR (1) BR9609324A (en)
CA (1) CA2224715A1 (en)
CO (1) CO4750713A1 (en)
CZ (1) CZ424297A3 (en)
HU (1) HUP9802320A3 (en)
IL (1) IL122844A0 (en)
NO (1) NO980016L (en)
PL (1) PL324346A1 (en)
SK (1) SK498A3 (en)
TR (1) TR199800001T1 (en)
WO (1) WO1997002285A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124453A (en) * 1995-07-04 2000-09-26 Novartis Ag Macrolides
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
US7368423B1 (en) * 2001-12-05 2008-05-06 The Scripps Research Institute Composition and method for treating chronic allograft rejection
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
AU2006259348B2 (en) 2005-06-17 2010-07-22 Novartis Ag Use of sanglifehrin in HCV
US8067024B2 (en) 2006-02-10 2011-11-29 Medtronic Vascular, Inc. Medical devices to prevent or inhibit restenosis
CN101289440B (en) * 2007-06-29 2010-08-25 中国热带农业科学院热带生物技术研究所 Polyene macrocyclic compounds, preparation thereof and applications
WO2010034243A1 (en) 2008-09-24 2010-04-01 Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences Novel gene cluster
WO2011098805A1 (en) 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
WO2011098808A1 (en) 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
EP2533784B1 (en) 2010-02-09 2015-04-22 Neurovive Pharmaceutical AB Sanglifehrin based compounds
GB201008123D0 (en) 2010-05-17 2010-06-30 Biotica Tech Ltd Novel compounds
UY33775A (en) 2010-12-10 2012-07-31 Gilead Sciences Inc MACROCYCLIC INHIBITORS OF VIRUS FLAVIVIRIDAE, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND AND THEIR USES
US9271977B2 (en) 2010-12-20 2016-03-01 Neurovive Pharmaceutical Ab Sanglifehrin derivatives and methods for their production
JO3063B1 (en) 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab Novel compound and methods for its production
GB201118334D0 (en) 2011-10-24 2011-12-07 Biotica Tech Ltd Novel dosage form
NZ724616A (en) 2012-06-08 2018-06-29 Gilead Sciences Inc Macrocyclic inhibitors of flaviviridae viruses
SG11201408047XA (en) 2012-06-08 2015-01-29 Gilead Sciences Inc Macrocyclic inhibitors of flaviviridae viruses
AR091279A1 (en) * 2012-06-08 2015-01-21 Gilead Sciences Inc MACROCICLIC INHIBITORS OF VIRUS FLAVIVIRIDAE
CN110062626A (en) 2016-11-18 2019-07-26 纽维制药有限公司 Purposes of the sanglifehrin Macrocyclic analogs as anticancer compound

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9318144D0 (en) * 1993-09-01 1993-10-20 Sandoz Ltd Organic compounds
WO1995015328A1 (en) * 1993-11-30 1995-06-08 Abbott Laboratories Macrocyclic immunomodulators with novel cyclohexyl ring replacements

Also Published As

Publication number Publication date
MX9800217A (en) 1998-07-31
HUP9802320A2 (en) 1999-02-01
EP0836616A1 (en) 1998-04-22
WO1997002285A1 (en) 1997-01-23
HUP9802320A3 (en) 1999-03-29
CA2224715A1 (en) 1997-01-23
IL122844A0 (en) 1998-08-16
SK498A3 (en) 1998-07-08
CZ424297A3 (en) 1998-04-15
JPH11509092A (en) 1999-08-17
TR199800001T1 (en) 1998-04-21
AU6519396A (en) 1997-02-05
CO4750713A1 (en) 1999-03-31
NO980016D0 (en) 1998-01-02
KR19990028724A (en) 1999-04-15
CN1193979A (en) 1998-09-23
NO980016L (en) 1998-03-02
BR9609324A (en) 1999-05-25
PL324346A1 (en) 1998-05-25
AU708004B2 (en) 1999-07-29

Similar Documents

Publication Publication Date Title
AR006514A1 (en) A MACROLID, ITS USES, A PROCESS TO PRODUCE IT, A BIOLOGICALLY PURE ISOLATE CAPABLE OF PRODUCING IT, AND A PHARMACEUTICAL COMPOSITION THAT IT INCLUDES
ATE92080T1 (en) ISOLATION AND STRUCTURE DETERMINATION OF THE CYTOSTATIC LINEAR DEPSIPEPTIDE DOLASTATIN 15.
KR100203556B1 (en) Novel cyclosporins
ES2093658T3 (en) CYCLIC POLYPEPTIDE WITH ANTIBIOTIC ACTIVITY, PROCEDURE FOR ITS PREPARATION AND PURE CULTIVATION OF A STRAIN OF COELOMYCETES.
DK366889A (en) peptide
ES2075115T3 (en) NEW POLYPEPTIDE COMPOUND AND A PROCEDURE FOR THE PREPARATION OF THE SAME.
DE69003168T2 (en) Isolation and structure determination of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13.
KR890000518A (en) Cyclic peptolide
LU90943I2 (en) Kineret-anakinra and its pharmaceutically acceptable derivatives
DE60036930D1 (en) HUMANESE CYTOKIN AS A LIGAND OF THE ZALPHA RECEPTOR AND ITS USES
ATE218581T1 (en) CYCLOSPORINE DERIVATIVE, PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION
GB2380675A (en) Method of increased bioavailability of nutrients and pharmaceutical preparations with tetrahydropiperine and its analogues and derivatives
BR9810002A (en) Preparation of chromatographically purified native <244> 1-at, process for preparing it, and using a support material
EA200100347A1 (en) METHOD AND COMPOSITION FOR THE TREATMENT AND PREVENTION OF TUBERCULOSIS
ES2097736T3 (en) CYCLIC PEPTIDE WITH ANTAGONIST ACTIVITY OF SUBSTANCE P AND SUBSTANCE K.
EP0362520A3 (en) Antibiotic mersacidine, process for producing it and its use as a medicament
ES2084599T3 (en) METHOD FOR PURIFYING ANTITROMBINE III AND PREPARATION OF ANTITROMBINE III CONTAINING SUCH ANTITROMBINE III.
AR004165A1 (en) A DICLAVULANATE SALT OF BIS- (2-DIALKYLAMINOALKYL) -ETER; A PROCEDURE TO PREPARE THE SAME; AND A PHARMACEUTICAL COMPOSITION THAT CONTAINS IT
DK0387712T3 (en) WS7622A, B, C and D substances, derivatives thereof and processes for their preparation and use thereof
PT98134A (en) (WS7622A) OBTAINED FROM THE CULTURE OF A STREPTOMYCES RESBTOMYCIFICUS N 0. 7622 AND OF PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AU7386094A (en) T-lymphocyte-containing pharmaceutical composition for treating infections
BR9910763A (en) Rotaviruses non-structural protein 4 (nsp4) antigenic composition, processes to protect a mammalian host against disease caused by rotaviruses, and to improve diarrheal symptoms in a mammalian host, isolated and purified nucleic acid sequence, plasmid containing a nucleic acid sequence isolated and purified host cell and process to produce an alternative form of rotavirus nsp4
JPH0338280B2 (en)
GB8928811D0 (en) An activator for damaged neurocytes for the prevention and treatment of disease
DK0662145T3 (en) Method for selectively increasing factor A of antibiotic GE 2270